Niche Science & Technology Ltd

Have you seen our latest Insider's insight?https://www.niche.org.uk/asset/insider-insight/Insider-Advisory-Boards.pdf

An ongoing problem and some helpful hints.

https://www.linkedin.com/pulse/top-tips-investigator-site-selection-tim-hardman/

Effective consensus-forming is looking for 'win-win' solutions where no decision that goes against the will of an individual or a minority.

www.linkedin.com

https://www.linkedin.com/pulse/data-everywhere-far-too-much-think-tim-hardman/?published=t&trackingId=0qzacBw%2FrJR8HWhE8wGMuw%3D%3D

Data, data everywhere… far too much to think The volume of scientific data published each year has exploded. Wisdom is out there but how can you find it? It is getting harder and harder to even rule out whether your own current research question has already been addressed.

https://www.linkedin.com/pulse/good-laboratory-practices-tim-hardman/

Good Laboratory Practices? Do you know your Good Laboratory Practices? These requirements describe the standards by which drug safety studies are conducted in nonclinical animal studies. Further to ensuring the ethical conduct and care of animals being studied, adhering to GLP regulations secures the validity, integrity, and

https://www.linkedin.com/pulse/april-fools-tim-hardman/?trackingId=A1HQuV%2B6VwB6cwUlEO9Z5w%3D%3D

April Fools By nature, scientists are not particularly good with humour. We are just a little too literal.

iOnctura awarded UK’s MHRA Innovation Passport for entry into innovative licensing and access pathway (ILAP).

https://fyi-news.co.uk/ioncturas-mhra-innovation-passport-award

https://www.linkedin.com/pulse/mandatory-adoption-european-clinical-trials-system-tim-hardman/

Mandatory adoption of the European Clinical Trials Information System approaches Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System (CTIS) persist as the deadline for compliance arrives. There will be a mad dash across Europe in the first few weeks of 2023 to complete the operational specifications of the new European clinical ...

Some challenges for the year ahead...

2023 – early regulatory considerations All those in the pharmaceutical industry hoping to ease themselves into 2023 following the excitement of 2022 (regulatory and otherwise) will face some disappointment. We find that there is a great deal to consider now that we have properly entered the New Year.

If you want to learn more about how we perform quality control reviews on clinical study reports at Niche Science & Technology Ltd, take a look at this article.
https://www.linkedin.com/feed/update/urn:li:activity:7017191009017028608/

Caitlin Tolbert on LinkedIn: Quality Control Tips When Reviewing Clinical Study Reports If you want to learn more about how we perform quality control reviews on clinical study reports at Niche Science & Technology Ltd, take a look at this article.

Season's Greetings from everyone at Niche Science & Technology Ltd.

We love to share the joy of science. When children (of all ages) have greater access to science tools at home – equipment like rulers, measuring cups and kitchen scales – and encouragement to tinker with them, it strengthens their interest and confidence in science (according to recent research).

https://lnkd.in/eu64qTQP

Christmas 2022 The festive season is upon us again. Never is it more relevant for us to be reminded of our society's impact on the environment than at this time of the giving and receiving of gifts. When children have greater access to science tools at home – equipment like rulers, measuring cups and kitchen sc...

https://www.linkedin.com/pulse/metathesiophobia-from-preclinical-clinical-tim-hardman/?trackingId=yKw%2F7sqOScqsDNLPRkzPQQ%3D%3D

Metathesiophobia: from Preclinical to Clinical Development Having worked in early-stage clinical pharmacology for over 30 years I have found that one of the biggest fears is the transition from preclinical to clinical investigations. And let’s face it, the fears are fair.

https://www.linkedin.com/pulse/top-10-horrifying-halloween-healthcares-tim-hardman/?trackingId=R0Rrom%2FASciMyQvHqUyHRA%3D%3D

Top 10: horrifying Halloween healthcares As a 40-year veteran of the study, modern medicine is starting to look like science fiction. If you are (perhaps) morbidly curious you will either need to take a voyage into the past to find your kicks (or horror films).

https://www.linkedin.com/pulse/e-mail-new-gender-battleground-tim-hardman/?trackingId=zQlsYBRwSnWHO5brC86ILA%3D%3D

E-mail: the (new) gender battleground The internet was set alight last week on the issue of differences in the approach to emails adopted by men and women. Interestingly, the originating post came from Emily Clarkson, the daughter of perhaps the most politically incorrect, un-woke individual ever to be gifted unfettered access to a tele

Thanks to everyone of you who took part in our two surveys over the course of the pandemic. Delighted to say that our findings are published today. If you are interested in finding out how your colleagues responded you can find the report here: https://journal.emwa.org/a-virtual-workforce/changes-to-working-practices-in-medical-communications-during-the-covid-19-pandemic-insights-from-two-surveys/

Reviewer 2 always has it in for us.

Art by Sketchplanations

A cornerstone of antiscience groups is protecting the core idea despite evidence to the contrary.

NO

Old but fornicating [Au] from

[Sgt Scholar Actual]

Tom Gauld New Scientist

Great to have had the chance to work on this project - "Could we identify a subgroup of severe asthma patients less likely to benefit from antimicrobial strategies at exacerbation or in the context of poor control?" https://doi.org/10.1111/all.15425…

https://www.linkedin.com/pulse/graduation-day-tim-hardman/

Graduation Day Son, I wanted to record this landmark day in your progress through life. Unlike many of the celebrations we have been through together, today marks your transition into manhood – whatever that means.

Twisteddoodles